Novel Classes to Drive Growth in Major European Oral Antidiabetic Markets
In its new therapy area insight series – Diabetes, IMARC Group, one of the world’s leading research and advisory firms, finds that Novel classes such as DPP-IV Inhibitors, GLP-Agonists and SGLT inhibitors will play a major role in driving the growth of major European Oral Antidiabetic markets. Findings from the reports suggest that in the …
Click here to read full Press Release